NEW YORK (GenomeWeb News) – Cancer molecular diagnostics developer Pathwork Diagnostics announced today a collaboration with Novartis for the discovery of cancer biomarkers.
The biomarkers will be used as a basis for diagnostics "across a range of cancer types," the Redwood City, Calif.-based firm said in a statement.
Under the terms of the deal, both companies have the rights to develop and commercialize the diagnostic products. Further terms were not disclosed.
Last month Pathwork Diagnostics received clearance from the US Food and Drug Administration for use of its microarray-based Tissue of Origin test with formalin-fixed embedded tissue.